Enfusion Dirección

Dirección controles de criterios 4/4

El CEO de Enfusion es Oleg Movchan , nombrado en Aug 2022, tiene una permanencia de 2.25 años. compensación anual total es $1.46M, compuesta por 44.7% salario y 55.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.24% de las acciones de la empresa, por valor de $15.72M. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 3.4 años, respectivamente.

Información clave

Oleg Movchan

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	44.7%
Permanencia del CEO	2.3yrs
Participación del CEO	1.2%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Dec 02

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Nov 08

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Oct 31

Enfusion Faces Cross-Currents In Investment Management Software Market

Aug 24

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11

Enfusion: Multiple Catalysts

Jun 20

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 08

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Dec 19

Enfusion Expands Offerings As Revenue Growth Decelerates

Oct 31

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 18

Enfusion gains after takeover report

Aug 31

Enfusion gets new interim CEO

Aug 22

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Aug 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Oleg Movchan en comparación con los beneficios de Enfusion?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$3m
Jun 30 2024	n/a	n/a	US$3m
Mar 31 2024	n/a	n/a	US$2m
Dec 31 2023	US$1m	US$650k	US$6m
Sep 30 2023	n/a	n/a	US$6m
Jun 30 2023	n/a	n/a	US$6m
Mar 31 2023	n/a	n/a	US$3m
Dec 31 2022	US$2m	US$236k	-US$9m

Compensación vs. Mercado: La compensación total de Oleg($USD1.46M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.38M).

Compensación vs. Ingresos: La compensación de Oleg ha sido consistente con los resultados de la empresa en el último año.

CEO

Oleg Movchan (50 yo)

2.3yrs

Permanencia

US$1,455,190

Compensación

Mr. Oleg Movchan has been a Non-Executive Director at Enfusion, Inc since 2021 and a Member of the Board of Managers of Enfusion Ltd. LLC since February 2009. He served as an Interim Chief Executive Office...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Oleg Movchan	CEO & Director	2.3yrs	US$1.46m	1.24% $ 15.7m
Bradley Herring	Chief Financial Officer	1.9yrs	US$1.11m	0.018% $ 224.9k
Neal Pawar	Chief Operating Officer	less than a year	US$3.04m	0.038% $ 477.0k
Stephen Malherbe	Managing Partner	no data	sin datos	1.06% $ 13.5m
Valeria Gutowski	Chief Accounting Officer	less than a year	sin datos	0.010% $ 127.2k
Daniel Groman	Chief Technology Officer	less than a year	sin datos	0.13% $ 1.7m
Ignatius Njoku	Head of Investor Relations	no data	sin datos	sin datos
Matthew Campobasso	General Counsel & Corporate Secretary	2yrs	sin datos	0.018% $ 224.2k
Bronwen Bastone	Chief People Officer	3.1yrs	US$1.86m	0.053% $ 670.0k
Joseph Defeo	Global Head of Managed Services Production	3.6yrs	sin datos	sin datos
Jeff Young	Head of Implementation	3.6yrs	sin datos	sin datos
Robert Taylor	Head of Client Support	3.6yrs	sin datos	sin datos

2.1yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ENFN se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Oleg Movchan	CEO & Director	3.8yrs	US$1.46m	1.24% $ 15.7m
Bradford Bernstein	Independent Non-Executive Director	3.8yrs	sin datos	1.21% $ 15.4m
Lawrence Leibowitz	Independent Non-Executive Director	3.8yrs	US$228.17k	0.17% $ 2.2m
Deirdre Somers	Independent Director	1.8yrs	US$462.87k	0.019% $ 246.4k
Kathleen DeRose	Independent Non-Executive Director	2.9yrs	US$228.17k	0.044% $ 562.0k
Jan Hauser	Independent Non-Executive Director	2.9yrs	US$234.67k	0.043% $ 549.4k
Roy Luo	Independent Non-Executive Director	3.8yrs	sin datos	sin datos
Michael Spellacy	Independent Chairman	1.8yrs	US$658.20k	0.030% $ 376.4k

3.4yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ENFN se considera experimentada (3.4 años de antigüedad promedio).

Enfusion Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Enfusion, Inc Announces Executive Appointments

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Recent updates

Consensus EPS estimates fall by 11%

New minor risk - Earnings quality

Why Private Equity Will Buyout Enfusion

New minor risk - Shareholder dilution

Enfusion, Inc Announces Executive Appointments

Enfusion, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Enfusion Reportedly in Talks with Investment Bankers to Evaluate Options, Include Potential Sale

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Enfusion: Growth Should Accelerate In Coming Quarters

Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Consensus EPS estimates increase by 51%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Enfusion, Inc. Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility

New minor risk - Shareholder dilution

Enfusion, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

New minor risk - Shareholder dilution

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Consensus EPS estimates fall by 38%

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 20%, revenue upgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

New minor risk - Shareholder dilution

Now 20% undervalued after recent price drop

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 22% undervalued

New minor risk - Shareholder dilution

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Enfusion: Product Is Sticky And Industry Is Huge

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

CEO & Director recently sold US$1.0m worth of stock

New minor risk - Shareholder dilution

CEO & Director recently sold US$1.5m worth of stock

CEO & Director notifies of intention to sell stock

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Managing Partner recently sold US$9.9m worth of stock

Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 32%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Shareholder dilution

Enfusion Faces Cross-Currents In Investment Management Software Market

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Enfusion, Inc. Appoints Andi Woolass as Head of Partnerships and Alliances for EMEA

Enfusion Reportedly Draws Takeover Interest from Private Equity, Irenic Capital

Enfusion: Multiple Catalysts

Now 21% undervalued after recent price drop

Price target decreased by 7.1% to US$11.21

Chief Technology Officer recently sold US$396k worth of stock

Chief Technology Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Chief Technology Officer recently sold US$126k worth of stock

Chief Technology Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop